INmune Bio Inc. - Common stock (INMB) News

INmune Bio Inc. - Common stock (INMB): $8.33

-0.27 (-3.14%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add INMB to Watchlist
Sign Up

Industry: Biotech


Ranked

of 401

in industry

Filter INMB News Items

INMB News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

INMB News Highlights

  • INMB's 30 day story count now stands at 4.
  • Over the past 20 days, the trend for INMB's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
  • The most mentioned tickers in articles about INMB are BIO, XPRO and ALT.

Latest INMB News From Around the Web

Below are the latest news stories about INMUNE BIO INC that investors may wish to consider to help them evaluate INMB as an investment opportunity.

INmune Bio, Inc. Announces Pre-Clinical Data That Support a Pioneering Approach to Treating Duchenne Muscular Dystrophy

Boca Raton, Florida, Jan. 25, 2023 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, in collaboration with Professor Armando Villalta, Ph.D. of University California, Irvine School of Medicine, has shown targeting soluble TNF (sTNF) using a Dominant-Negative TNF (DN-TNF) biologic significantly decreased muscle damage in a murine mdx model of Du

Yahoo | January 25, 2023

INmune Bio: INKmune For Solid Tumors And Other Potential Catalysts

Thesis

INmune Bio, Inc. (INMB) is the odd one out among the many biotech companies I have studied. I have done a deep dive into their two main drugs, as well as looked at competitors. My understanding of the science, and early data comparisons, suggests that both XPro and INKmune have a good probability of being very successful

I have covered the company before regarding its drug XPro for Alzheimer's disease, mild cognitive impairment and treatment-resistant depression. The company has received a no-objection letter t...

E. Roudasev on Seeking Alpha | January 5, 2023

INmune Bio: INKmune For Solid Tumors And Other Potential Catalysts (NASDAQ:INMB)

INmune Bio has multiple potential catalysts ahead including the go-ahead to start Phase 2 trials with XPro in the US. Click here to find out why INMB is a Buy.

Seeking Alpha | January 5, 2023

INmune Bio, Inc., Virginia Commonwealth University, and Barrow Neurological Institute Receive Department of Defense Funding to Study the Role of Traumatic Brain Injury in the Development of Alzheimer’s Disease

XPro1595 decreases development of amyloid beta and tau following TBI in murine model of Alzheimer’s disease Boca Raton, Florida, Dec. 22, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease in concert with Virgina Commonwealth University (VCU) and Barrow Neurological Institute have received a grant from the Department of Defense (DoD). The gr

Yahoo | December 22, 2022

Wall Street Analysts Predict a 99% Upside in INmune Bio, Inc. (INMB): Here's What You Should Know

The mean of analysts' price targets for INmune Bio, Inc. (INMB) points to a 98.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Yahoo | December 21, 2022

INmune Bio, Inc. Data at ASH Highlight Innovative Natural Killer Cell Therapeutic Platform Showing 100+ Day Persistence of Cancer Killing Memory Like NK Cells in Patients with AML/MDS Following Treatment with INKmune™

Boca Raton, Florida, Dec. 08, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (“INMB” or “the Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease will present data from UK patients with MDS or AML treated with INKmune™ at the annual American Society for Hematology (ASH) Conference held in New Orleans December 10th – 13th. The clinical team at Southampton University in the UK, led by Professor Ki

Yahoo | December 8, 2022

INmune Bio, Inc. Reports Combination Therapy with INB03™ Overcomes Resistance to Trastuzumab-Deruxtecan in MUC4 expressing HER2+ Breast Cancer

Neutralizing soluble TNF with INB03™ overcomes resistance to trastuzumab-deruxtecan in MUC4 expressing HER2+breast cancer. Combination therapy of INB03™ and trastuzumab-deruxtecan presented at the 45th annual San Antonio Breast Cancer Symposium today Boca Raton, Florida, Dec. 06, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, has been i

Yahoo | December 6, 2022

INmune Bio, Inc. Focused on Novel Clinical Trial Designs to Advance Next Generation of Alzheimer’s Disease Treatments

INmune Bio, a leader in novel therapies and innovative trial design for AD participates in 15th CTAD conference in San Francisco November 29th to December 2nd Boca Raton, Florida, Nov. 29, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease will participate in the 15th CTAD Conference in San Francisco November 29th to December 2nd. “This year

Yahoo | November 29, 2022

INmune Bio, High Risk, Higher Reward (NASDAQ:INMB)

INmune Bio has two clinical stage drugs with promising early results. Click here to read my analysis of INMB stock.

Seeking Alpha | November 21, 2022

Quite a few insiders invested in INmune Bio, Inc. (NASDAQ:INMB) last year which is positive news for shareholders

Generally, when a single insider buys stock, it is usually not a big deal. However, when several insiders are buying...

Yahoo | November 20, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 2.9173 seconds.